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Mitochondrial Dysfunction’s Role in the Pathogenesis of Autism Spectrum Disorder:
A Proposed Pathway
Vaughan Schwob

There are many contributing factors to the pathogenesis of Autism Spectrum Disorder
(ASD). There are several findings related to dysfunctions in ASD; the most common are
mitochondrial dysfunction, overactivation of the glia in the brain’s immune system, and reduced
synaptic pruning (Petrelli, Pucci, & Bezzi, 2016; Yanuck, 2019). This literature review analyzes
the research associating oxidative stress with the increase in cytokine and chemokine levels and
how that pathway leads to the activation of the immune system. Immune system activation
during brain development is the factor in ASD’s pathology that has the most evidence supporting
its role in the development of ASD.
1. Introduction
Autism Spectrum Disorder (ASD) is one of the most common neurodevelopmental
disorders. One in fifty-four children is diagnosed with ASD in the United States (McPartland et
al., 2012). A diagnosis of ASD requires meeting all of the social-communicative criteria and two
of the four restrictive and repetitive behaviors criteria (APA, 2013). Frequently, people with ASD
have difficulty with their executive function-related tasks (Blijd-Hoogewys et al., 2014).
Specifically, the deficits are often in cognitive flexibility and planning/organization. Other
common characteristics of people with ASD are difficulties taking another person’s perspective,
understanding social reciprocity, taking the initiative, adapting to change (rigid and pervasive
behaviors), and using self-regulation (Blijd-Hoogewys et al., 2014). People typically diagnosed
with autism also commonly have sensory sensitivities; strong scents and loud sounds can cause
severe distress. A less widely known symptom is a deficit in episodic memory. The
characteristics of ASD are widely varied, which makes studying and researching the disorder
more difficult.

The exact etiology of ASD is unknown. It is most likely caused by a combination of
genetic and environmental factors. The most basic causal understanding is that there are brain
structure and function abnormalities in people with ASD. The commonly seen cause of ASD is a
lack of synaptic pruning during brain development (Tye et al., 2019). Current research is focused
on how synaptic pruning deficits occur. There are many factors that could contribute to deficits
in synaptic pruning; the potential pathway examined in this paper is how mitochondria
dysfunction can lead to oxidative stress leading to increases in chemo/cytokines and an overly
activated immune system (as represented by increased levels of cytokines and chemokines). An
overly activated immune system during brain development has connections to synaptic pruning
deficits (Tang et al., 2014; Nicolini et al., 2015).

Figure 1. Pathway overview
1.1 Mitochondrial homeostasis linked to ASD
Mitochondrial dysfunction has been linked to ASD (Giulivi et al., 2010; Goodenowe &
Pastural, 2011). Genetic mutations targeting mitochondrial function account for more than 10%
of all cases, which is the largest genetic contribution (Goodenowe & Pastural, 2011). A
Portuguese study showed that 7% of autistic cases are correlated with mitochondrial respiratory
chain disorders, meaning this could be one of the most common disorders associated with autism
(Olivieria et al., 2005). Not every child in the Oliviera study was tested for a mitochondrial
disorder; therefore the actual prevalence is most likely higher. Mitochondria dysfunction is most
likely a large part of the pathogenesis of ASD.

One of the most likely ways that mitochondrial dysfunction can contribute to the
pathogenesis of ASD is through producing reactive oxygen species (ROS). A disturbance in the
mitochondrial respiratory chain can lead to assembly deficits and structural changes in the
oxidative phosphorylation complexes (Morán et al., 2012). Those changes lead to decreased ATP
production, electron leakage, accumulation of ROS, and release of apoptotic inducing factors
(Morán et al., 2012). Complexes I and III are the primary sites that produce oxygen radicals
(Morán et al., 2012). Without a functioning mitochondrial respiratory system, more oxygen
radicals are produced, and the build-up can lead to oxidative stress (Morán et al., 2012).
1.2 Oxidative Stress
Oxidative stress is caused by an imbalance between the production and accumulation of
reactive oxygen species (ROS) in cells and tissues and the ability of a biological system to
detoxify these reactive products (Pizzino et al., 2017). ROS play a role in cell signaling (Pizzino
et al., 2017). They are typically generated as by-products of oxygen metabolism (Pizzino et al.,
2017). ROS are usually produced in the mitochondria (Pizzino et al., 2017). During oxidative
stress, there is an excess amount of free radicals and oxidants (Pizzino et al., 2017). Oxidative
stress can be responsible for the induction of diseases, both chronic and degenerative (Pizzino et
al., 2017). Hyperoxia can upregulate the production of TNF and IL-1 (Ghezzi et al. 1991). ROS
positively regulate the production of cytokines (Sozzani et al., 2005). Oxidative stress influences
many cellular processes.
The focus of this review will be ROS’s effects on the immune system. In the immune
system, pathogen-associated molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs) can stimulate ROS production through stimulation of the mitochondria (Yang

et al., 2013). ROS can lead to inflammasome activation, which stimulates caspase-1 and the
maturation of cytokines (Yang et al., 2013).
1.3 Cytokines and Chemokines
The immune system produces cytokines, chemokines, and other humoral factors to
protect the host when threatened (Cerami, 1992). This system usually restores normal
homeostasis, but the overproduction of immunoregulatory mediators can prove deleterious to the
host (Cerami, 1992). Cytokines and chemokines are signaling molecules for the immune system
that can tag cells for destruction by leukocytes (Nathan & Sporn, 1991).
Cytokines and chemokines have been implicated in the pathogenesis of ASD. A mouse
model study found that ASD-like behavior in offspring may be caused by altered levels of
maternal cytokines (TNFα, IL1β, IL-2, IL-6, and IL-10) (Petrelli, Pucci, & Bezzi, 2016; Jones et
al., 2017). Maternal inflammatory cytokines crossing the placental barrier is the potential
mechanism by which maternal immune dysregulation increases the risk for ASD.
Proinflammatory cytokines in the developing brain lead to neuroinflammation and gliosis.
Researchers hypothesize that the inflammatory response contributes to the pathogenesis of ASD
(Jones et al., 2017; Estes & McAllister, 2015; Keil et al., 2010; Meyer, Ingersoll, & Hambrick,
2011).
2. Dysfunctions of the mitochondria found in ASD
Several studies have shown that mitochondrial dysfunction is common in people with
ASD (Giulivi et al., 2010; Goodenowe & Pastural, 2011; Haas, 2010; Oliveira et al., 2005).
Giulivi and colleagues (2010) examined mitochondria dysfunction in people with ASD by
measuring oxidative phosphorylation capacity, mtDNA copy number and deletions,
mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate. The

Giulivi et al. study found that mitochondrial oxygen consumption was impaired in peripheral
lymphocytes in children with ASD. Giulivi and colleagues’ study also discovered higher plasma
pyruvate levels and higher rates of hydrogen peroxide production in children with ASD.
However, this study was purely correlational, so the evidence needs to be further supported by
other research. A study by Haas (2010) found that the most common mtDNA mutation is the
MELAS A3243G mutation. Oliveira and colleagues (2005) performed a population study with a
population of Portuguese children. They assessed the metabolic dysfunction in autism hypothesis
using lactate and pyruvate levels for their analysis. Plasma lactate levels were elevated in 20.3%
of the participants (Oliveria, 2005). This study also found a defect in oxidative phosphorylation
associated with ASD. However, these results are not as trustworthy as other findings because
there were no follow-up studies and their analyses were not well thought out. Therefore, their
findings would need to be confirmed by other studies. Overall, there are strong correlations
between mitochondrial dysfunction and ASD using several markers of mitochondrial
dysfunction. Consequently, it is reasonable to conclude that mitochondrial dysfunction plays a
role in the pathogenesis of ASD.
3. Mitochondrial dysfunction increasing oxidative stress levels
The mitochondria consumes ~85-95% of all oxygen inhaled during respiration. Most of
the oxygen that passes through the mitochondria is reduced to water in the final step of the
respiratory chain (Shigenaga, Hagen, & Ames, 1994). Even when the respiratory chain is
functioning normally 0.1-4% of the electrons flowing through leak out and cause single-electron
reduction of oxygen and thus forming a free radical superoxide anion (O2•−; Murphy, 2009).
Complexes I and III are thought to be the primary sites that leak electrons and form O2•− (Morán
et al., 2010). O2•− is eliminated by the enzyme superoxide dismutase, the enzyme dismutases O2•−

into H2O2 (Morán et al., 2012). When the mitochondria is dysfunctional and the respiratory chain
is damaged O2•− is increased and can favor the accumulation of ROS (Morán et al., 2012).
The dysfunction of the mitochondria that is relevant to ASD is mitochondrial disorders.
In primary mitochondrial diseases, the respiratory chain is dysfunctional (Morán et al., 2012).
The dysfunction in the respiratory chain leads to disturbances in the electron transport and proton
pumping across the membrane (Morán et al., 2012). The main mitochondrial dysfunction seen in
ASD is decreased levels of complexes in the electron transport chain (Siddiqui, Elwell, &
Johnson, 2016; Tang et al., 2013; Gu et al., 2013). Siddiqui, Elwell, & Johnson (2016) found
reduced levels of complexes III and V. A study by Tang and colleagues (2013) found reduced
levels of all ETC complexes except II in children with ASD. Gu and colleagues (2013) found
decreased pyruvate dehydrogenase activity in post-mortem frontal cortex tissue of people with
ASD. Reduced levels of pyruvate dehydrogenase would result in insufficient removal of
pyruvate and lactate for the TCA cycle leading to insufficient ATP generation (Gu et al., 2013).
The mitochondrial dysfunction seen in ASD leads to an increase in mitochondrial ROS (mtROS)
(Manivasagam et al., 2020).

Figure 2. Reduced concentrations of ETC complexes and electron leakage points.
4. mtROS causes dysregulation of cytokines and chemokines
As stated earlier PAMPs and DAMPs can stimulate ROS production by stimulating the
mitochondria (Yang et al., 2013). ROS can cause thioredoxin-interacting protein (TXNIP) to
dissociate from thioredoxin (TRX), which allows TXNIP to bind to Nod-like receptor pyrin
domain-containing 3 (NLRP3), which leads to NLRP3 inflammasome activation (Yang et al.,
2013). Then NLRP3 inflammasome then activates caspase-1, which catalyzes the proteolytic
maturation of pro-inflammatory cytokines IL-1β and IL-18 (Yang et al., 2013). Mitochondrial
ROS (mtROS) can also promote pro-inflammatory cytokine production without using an
inflammasome by inactivating MAPK phosphatase, which inhibits pro-inflammatory cytokine
gene transcription (Yang et al., 2013). Nakahira et al. (2011) and Zhou et al. (2011) showed that
increased mitochondria-derived ROS caused by respiratory chain inhibitors lead to enhanced

NLRP3-dependent caspase-1 activation and IL-1β secretion. ROS from the mitochondria have
been proposed to mediate inflammasome activation (Yang et al., 2013). mtROS mediating the
NLRP3 inflammatory response can lead to increased amounts of inflammatory cytokines
(Nakahira et al., 2011).

Figure 3. Diagram of inflammatory cytokine production dependent and independent of
inflammasome activation.
The Nakahira et al. (2011), Zhou et al. (2011), and Bulua et al. (2011) studies all indicate
that mtROS act as signaling molecules to trigger proinflammatory cytokine production. Bulua
and colleagues designed a cellular experiment to confirm that mitochondria are the cellular
source of excessive ROS. They found that inhibiting mtROS production inhibited MAPK
activation and production of IL-6 and TNF. The findings showed that with less mtROS
production there were fewer inflammatory cytokines in the cells. Therefore, it can reasonably be

concluded that mtROS cause dysregulation in the production of inflammatory cytokines and
chemokines. An overproduction of inflammatory cytokines leads to neuroinflammation.
5. Immune system dysregulation causing synaptic pruning deficits
Neuroinflammation is increased in ASD. A study by Takano (2015) found that
inflammatory cytokines, a signaling molecule that increases inflammation, are increased in
postmortem brain tissue taken from patients with ASD (Takano, 2015). Noreiga and colleagues
(2014) also reported altered cytokine profiles in patients diagnosed with ASD. Increased
cytokine production of IL-1β, IL-6, and IL-18 were found in the postmortem brains of people
with ASD (Noreiga et al., 2014; Takano, 2015). The increased levels of inflammatory cytokines
indicate increased microglial activation and expression because microglia are one of the main
producers of inflammatory cytokines (Noreiga et al., 2014). The cytokine increase that is found
in ASD is a common research finding; since several studies show the same increased cytokine
profile in people with ASD, which adds confidence to the findings.
Neuroinflammation is the inflammatory response that occurs within the brain and spinal
cord. The inflammation is mediated by cytokines, chemokines, reactive oxygen species, and
other secondary messengers (DiSabato, Quan, & Godbout, 2017). These mediators are produced
by microglia, astrocytes, endothelial cells, and peripheral immune cells. Common cytokines
involved in neuroinflammation are IL-1β, IL-6, and IL-18 (Petrelli, Pucci, & Bezzi, 2016).
Neuroinflammation can be damaging to the brain and cause neural circuitry to lose integrity
through glial activation.
Proinflammatory cytokines in the brain can lead to neuroinflammation and gliosis by
activating the brain’s immune system. Researchers hypothesis that the inflammatory response
contributes to the pathogenesis of ASD (Jones et al., 2017; Estes & McAllister, 2015; Keil et al.,

2010; Meyer, Ingersoll, & Hambrick, 2011). Specifically, that reactive gliosis might disturb
microglia’s ability to modulate the maturation, elimination, and functioning of synaptogenesis
(Petrelli, Pucci, & Bezzi, 2016; Malkova et al., 2012; Knuesel et al., 2014). Microglia are
essential in monitoring and maintaining synapses in the brain by regulating synaptogenesis and
neuronal maturation/activity (Paolicelli et al., 2011). They do this by engulfing synaptic material.
During reactive gliosis, microglia do not engulf synaptic material which leads to a lessening of
synaptic pruning. Decreased synaptic pruning is the largest hallmark of ASD and is thought to be
one of the main contributing factors to the symptoms and pathology seen in people with ASD
(Petrelli, Pucci, & Bezzi, 2016; Estes & McAllister, 2015).
6. Conclusion
As demonstrated throughout this paper mitochondrial dysfunction starts a pathway
leading to reactive gliosis and decreased synaptic pruning. Mitochondrial dysfunction is one of
the most common secondary disorders found in people with ASD (Goodenowe & Pastoral,
2011). Mitochondrial dysfunction produces superoxide with then transforms into hydrogen
peroxide which is a reactive oxygen species (Siddiqui, Elwell, & Johnson, 2016; Tang et al.,
2013). ROS are DAMPs that cause an increase of ROS in the system which then leads to the
production of inflammatory cytokines and reactive gliosis (Petrelli, Pucci, & Bezzi, 2016).
During reactive gliosis normal synaptic pruning does not occur which leads to a higher amount
of synapses than are present in a neurotypical brain (Paolicelli et al., 2011). Decreased synaptic
pruning and an overabundance of synapses is the hallmark of brains with ASD (Blijd-Hoogewys
et al., 2014). While the pathway discussed has not been confirmed by other research. Its logic
aligns with what research has shown. The next research step would be to confirm the connections
suggested in this pathway.
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